Article By:
The Tokenist
Friday, March 8, 2024 2:48 PM EDT
Short squeeze events are heralded by high short interest, trading volume spike, rapid stock price rise, and short interest ratio. Here are three stocks with the potential for a short squeeze in March.
Novavax Cracks Below Support: Are Things Getting Ugly?
Sounds like $NVAX is going to see some hard times if they can't get on the covid bandwagon.
Astrazeneca Vs. Novavax: Which Vaccine Stock Is A Better Buy?
The article isn’t wrong based off currently commercialized products (we have none)... and there is a chance that things could still end badly for $NVAX. But the odds are so much in our favor now that, at least for the next few weeks, investing in NVAX is like printing free money.
Astrazeneca Vs. Novavax: Which Vaccine Stock Is A Better Buy?
This article states the #Novavax $NVAX is overvalued. Market cap? Revenue potential?
Novavax Analyst Says COVID-19 Vaccine Could Net $400M In Yearly Sales
Analyst can actually think a #Covid19 vaccine will only cost $.40 each since $NVAX has stated that they expect to produce 1 billlion doses in 2021, does he?